Morgan Stanley Coherus Bio Sciences, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 826,977 shares of CHRS stock, worth $611,962. This represents 0.0% of its overall portfolio holdings.

Number of Shares

826,977

Previous 1,556,850 46.88%

Holding current value

$611,962

Previous $2.69 Million 68.07%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.99 - $1.8 $722,574 - $1.31 Million	-729,873 Reduced 46.88%	826,977 $860,000
Q2 2024 Oct 17, 2024	SELL	$1.58 - $2.51 $1.75 Million - $2.78 Million	-1,107,319 Reduced 41.56%	1,556,850 $2.69 Million
Q2 2024 Aug 14, 2024	SELL	$1.58 - $2.51 $1.75 Million - $2.78 Million	-1,107,319 Reduced 41.56%	1,556,850 $2.69 Million
Q1 2024 Oct 17, 2024	BUY	$2.02 - $3.14 $2.24 Million - $3.48 Million	1,107,319 Added 71.13%	2,664,169 $6.37 Million
Q1 2024 Aug 16, 2024	BUY	$2.02 - $3.14 $1.2 Million - $1.87 Million	594,316 Added 28.71%	2,664,169 $6.37 Million
Q1 2024 May 15, 2024	BUY	$2.02 - $3.14 $1.2 Million - $1.87 Million	594,316 Added 28.71%	2,664,169 $6.37 Million
Q4 2023 Aug 16, 2024	BUY	$1.59 - $3.85 $815,674 - $1.98 Million	513,003 Added 32.95%	2,069,853 $6.89 Million
Q4 2023 Feb 13, 2024	SELL	$1.59 - $3.85 $1.86 Million - $4.51 Million	-1,172,374 Reduced 36.16%	2,069,853 $6.89 Million
Q3 2023 Nov 15, 2023	BUY	$3.74 - $5.45 $849,380 - $1.24 Million	227,107 Added 7.53%	3,242,227 $12.1 Million
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $9.5 Million - $20.8 Million	2,505,776 Added 491.96%	3,015,120 $12.9 Million
Q1 2023 May 15, 2023	SELL	$5.89 - $10.52 $1.21 Million - $2.15 Million	-204,647 Reduced 28.66%	509,344 $3.48 Million
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $73,759 - $130,537	12,963 Added 1.85%	713,991 $5.65 Million
Q3 2022 Nov 14, 2022	SELL	$7.17 - $13.87 $803,814 - $1.55 Million	-112,108 Reduced 13.79%	701,028 $6.74 Million
Q2 2022 Oct 27, 2022	BUY	$5.86 - $13.23 $1.33 Million - $3 Million	227,083 Added 38.75%	813,136 $5.89 Million
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $1.33 Million - $3 Million	227,083 Added 38.75%	813,136 $5.89 Million
Q1 2022 Oct 27, 2022	SELL	$10.92 - $16.41 $2.48 Million - $3.73 Million	-227,083 Reduced 27.93%	586,053 $7.57 Million
Q1 2022 May 13, 2022	BUY	$10.92 - $16.41 $2 Million - $3 Million	182,755 Added 45.32%	586,053 $7.57 Million
Q4 2021 Feb 14, 2022	SELL	$15.81 - $18.99 $434,237 - $521,579	-27,466 Reduced 6.38%	403,298 $6.44 Million
Q3 2021 Nov 15, 2021	BUY	$12.68 - $17.79 $5.46 Million - $7.66 Million	430,764 New	430,764 $6.92 Million

Others Institutions Holding CHRS

# of Institutions

135

Shares Held

77.9M

Call Options Held

40.7K

Put Options Held

50.1K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $57.5M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account